Osteoporosis Dima L Diab MD FACE FACP CCD

Osteoporosis Dima L. Diab, MD, FACE, FACP, CCD Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism University of Cincinnati College of Medicine Bone Health and Osteoporosis Center Metabolic Bone Diseases and Mineral Disorders

Osteoporosis Definition: NIH Consensus Conference 1 • A skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture • Bone strength = Bone quantity (BMD) + Bone quality Osteoporotic bone 2 Normal bone NIH Consensus Statement March 2000 2 JBMR 1986; 1: 15 -21 1

World Health Organization (WHO) Diagnostic Criteria The WHO Study Group, 1994

T-scores and Z-scores Areal bone mineral density (BMD) is expressed in absolute terms of grams of mineral per square centimeter scanned (g/cm 2) and as a relationship to two norms: (a) compared to a young-adult reference population (T-score), (b) compared to the BMD of an age -, sex-, and ethnicity-matched reference population (Z-score). A Z-score of -2. 0 or lower is considered abnormally low for a person’s age, sex and race.

Secondary Osteoporosis Evaluation • Careful history and examination • Laboratory testing (minimum): - CBC - Complete metabolic panel (including Cr, Ca, phos, alkaline phosphatase, LFT’s) - 25 -OH vitamin D - 24 -hr urine calcium, sodium and creatinine - Testosterone (in men) • Identifies ~90% of occult disorders at a reasonable cost JCEM 2002; 87: 4431 -4437.

Additional Testing In Selected Patients - TSH if symptomatic, elderly or on treatment - PTH - SPEP, UPEP, immunofixation / light chains - 24 -hr urine free cortisol - estradiol (in premenopausal women with oligo- or amenorrhea) - celiac disease abs - iron studies if hemochromatosis is suspected - testing for mastocysis (histamine metabolites) - testing for HIV - BTM’s - bone biopsy in rare cases

Indications for DXA testing NOF Clinician’s Guide • Consider BMD testing in the following individuals: • Women age 65 and older and men age 70 and older, regardless of clinical risk factors • Younger postmenopausal women, women in the menopausal transition, and men age 50 to 69 with clinical risk factors for fracture • Adults who have a fracture at or after age 50 • Adults with a condition (e. g. RA) or taking a medication (e. g. glucocorticoids) associated with low bone density or bone loss NOF Clinician’s Guide to Prevention and Treatment of Osteoporosis 2014

FRAX®: WHO Fracture Risk Assessment Tool • Developed by WHO to evaluate fracture risk of patients from data from NA, Europe, Australia, Asia • Integrates clinical risk factors and femoral neck BMD • Estimates 10 -year patient-specific absolute fracture risk - Hip >3% - Major osteoporotic fracture (spine, forearm, hip, or humerus) >20% https: //www. shef. ac. uk/FRAX

Clinical Risk Factors Included in the FRAX Tool https: //www. shef. ac. uk/FRAX

FRAX Example

FRAX Benefits • BMD + CRFs predict fracture risk better than BMD or CRFs alone • Can be used without BMD when DXA is not available • Quantitative assessment of fracture risk

FRAX Limitations • Does not apply to premenopausal patients • Does not apply to treated patients • Does not include all risk factors – Important risk factors not considered (falls, BTMs, etc. ) – Yes or No response to CRFs does not consider range of risk (e. g. smoking, alcohol) – May underestimate or overestimate fracture risk • Does not quantify risk factors; e. g. : – 3 personal pelvis fractures = 1 ankle fracture – 5 mg prednisone for 3 months 2 years ago = 60 mg prednisone daily now • BMD input limited to femoral neck – Cannot use BMD of the spine or forearm

Approved Therapies for Osteoporosis Antiresorptive Agents • Calcitonin • Raloxifene (SERM) • Bisphonates - Alendronate - Risedronate - Ibandronate - Zoledronic acid • Denosumab (RANKL ab) Anabolic Agents • Teriparatide (PTH 1 -34) • Abaloparatide (PTHr. P analog)

Case 1 • A 70 -year-old woman falls and sustains a fracture of her right hip. She takes calcium supplementation but no other supplements or medications. • Physical examination is unremarkable. • A dual energy x-ray absorptiometry (DXA) scan reveals a T-score of -3. 4 in the left femoral neck.

• Laboratory studies show the following: Ø Calcium 8. 7 mg/d. L (normal, 8. 5 - 10. 5) Ø Phosphorus 3. 0 mg/d. L (normal, 2. 5 - 4. 5) Ø PTH 80 pg/m. L (normal, 10 - 60) Ø 25 -(OH) D 8 ng/m. L (normal, 30 - 80) Ø 1, 25 -(OH)2 D 50 pg/m. L (normal, 15 - 65) Ø Albumin 3. 8 g/d. L (normal, 3. 5 - 5. 4) Ø Urinary calcium 30 mg/24 hours (normal, 100300)

Question #1 Which of the following should be recommended initially? A. B. C. D. E. Vitamin D Raloxifene Alendronate Denosumab Teriparatide

Answer #1 Which of the following should be recommended initially? A. Vitamin D Ø This patient has severe vitamin D deficiency which needs to be treated before any other pharmacologic intervention for osteoporosis. Ø Her 25 -hydroxyvitamin D level is extremely low, in single digits, and has resulted in hypocalciuria and secondary hyperparathyroidism. A diagnosis of osteomalacia should be considered in this clinical scenario. B. Raloxifene C. Alendronate D. Denosumab E. Teriparatide

Which of the following should be recommended initially? A. Vitamin D B. Raloxifene C. Alendronate D. Denosumab E. Teriparatide Ø All the other listed options (answers B, C, D, and E) are approved therapies for osteoporosis and would not be the best initial treatment for this patient. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96: 1911 -1930.

Case 1 (cont’d) She was treated with vitamin D, and repeat laboratory studies several months later revealed the following: Ø Ø Ø 25 -(OH) D 34 ng/m. L (normal, 30 - 80) Calcium 9. 8 mg/d. L (normal, 8. 5 - 10. 5) Albumin 4. 2 g/d. L (normal, 3. 5 - 5. 4) PTH 60 pg/m. L (normal, 10 - 65) Creatinine 0. 9 mg/d. L (normal, 0. 6 - 1. 2) Urinary calcium 150 mg/day (normal, 100 - 300)

Case 1 (cont’d) • A repeat DXA scan a year later reveals a Tscore of -2. 6 in the left femoral neck. • Upon further questioning, she reports history of breast cancer s/p radiation therapy and history of DVT. • She also reports difficulty swallowing due to an esophageal stricture.

Question #2 Which of the following would you recommend to treat her osteoporosis at this time? A. B. C. D. E. Raloxifene Alendronate Zoledronic acid Teriparatide No treatment is necessary at this time

Answer #2 Which of the following would you recommend to treat her osteoporosis at this time? A. Raloxifene B. Alendronate C. Zoledronic acid Ø Zoledronic acid (an intravenous bisphonate) as the best treatment option for this patient’s osteoporosis. D. Teriparatide E. No treatment is necessary at this time

Which of the following would you recommend to treat her osteoporosis at this time? A. Raloxifene Ø Raloxifene (a SERM) is associated with an increased risk of VTE. B. Alendronate Ø Alendronate (an oral bisphonate) should be avoided in view of her esophageal stricture. C. Zoledronic acid D. Teriparatide E. No treatment is necessary at this time

Which of the following would you recommend to treat her osteoporosis at this time? A. Raloxifene B. Alendronate C. Zoledronic acid D. Teriparatide Ø Teriparatide (recombinant PTH) is contraindicated in patients who have had radiation therapy to the skeleton. E. No treatment is necessary at this time Ø This patient has osteoporosis based on her T-score level (< -2. 5) and should be treated to decrease her fracture risk. Ø Note that denosumab (RANKL inhibitor, not provided as an option here) would be ideal in patients with renal impairment as it is not cleared by the kidney. NOF Clinician’s Guide to Prevention and Treatment of Osteoporosis 2014

Case 2 • A 42 -year-old man falls and sustains a Colles’ fracture of his left wrist. He has no history of sexual dysfunction and does not take any medications. • A DXA scan reveals a Z-score of -2. 2 in the spine.

Case 2 (cont’d) • Ø Ø Ø His initial laboratory studies reveal the following: Calcium 8. 9 mg/d. L (normal, 8. 5 - 10. 5) 25 -(OH) D 12 ng/m. L (normal, 30 - 80) Urinary calcium 50 mg/24 hours (normal, 100 - 300) • He was treated with vitamin D, and repeat laboratory studies 3 months later revealed the following: Ø 25 -(OH) D 32 ng/m. L (normal, 30 - 80) Ø Urinary calcium 80 mg/24 hours (normal, 100 - 300)

Question #3 Which of the following tests is most likely to explain these findings? A. B. C. D. Serum intact PTH level Serum testosterone level Serum TSH level Serum antibodies for gluten-sensitive enteropathy E. Serum protein electrophoresis

Answer #3 Which of the following tests is most likely to explain these findings? A. Serum intact PTH level B. Serum testosterone level C. Serum TSH level D. Serum antibodies for gluten-sensitive enteropathy Ø In this young man, secondary causes of low bone density must be investigated. He was found to have vitamin D deficiency, but treating this deficiency did not correct his hypocalciuria, which should point to the diagnosis of celiac disease. Ø The most appropriate test to screen for this condition is serum antibodies for gluten-sensitive enteropathy, such as tissue transglutaminase antibodies. E. Serum protein electrophoresis

Which of the following tests is most likely to explain these findings? A. Serum intact PTH level B. Serum testosterone level C. Serum TSH level D. Serum antibodies for gluten-sensitive enteropathy E. Serum protein electrophoresis Ø The other options listed may be useful in evaluating patients with abnormally low bone mineral density, but these do not test for conditions associated with vitamin D deficiency and do not explain the clinical findings in this scenario. Ø The patient is not hypercalcemic and is not reported to have signs or symptoms of hypogonadism or thyroid dysfunction. Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract. 2013; 19: 120 -128.

Case 3 • A 68 -year-old postmenopausal Caucasian woman has a DXA scan to test for osteoporosis. She recently sustained a wrist fracture (tripped while walking). • She takes OTC calcium and vitamin D supplements. She has no history of chronic glucocorticoid use. • She does not smoke or drink alcohol excessively. Her mother fractured her hip at age 86.

Case 3 (cont’d) • Physical examination reveals mild thoracic kyphosis but is otherwise unremarkable, with no spine tenderness to palpation. • Her bone density test reveals a T-score of -2. 1 in the left femoral neck. • Her calculated 10 -year risk of a major fracture is 27% and hip fracture is 5. 7%.

Question #4 Which of the following is the most appropriate next step in her management? A. Continue calcium and vitamin D replacement therapy but no additional treatment for her low BMD at this time B. Start osteoporosis therapy C. Start osteoporosis therapy only if spine imaging reveals a vertebral compression fracture D. Repeat DXA scan in 3 -5 years since she does not have osteoporosis

Answer #4 Which of the following is the most appropriate next step in her management? A. Continue calcium and vitamin D replacement therapy but no additional treatment for her low BMD at this time B. Start osteoporosis therapy Ø This patient is at high risk of fracture based on her FRAX calculation (her 10 -yr risk of major fx is >20% and hip fx is >3%). Ø Therefore, she should be offered treatment for her low bone density even though she does not meet osteoporosis T-score criteria. C. Start osteoporosis therapy only if spine imaging reveals a vertebral compression fracture D. Repeat DXA scan in 3 -5 years since she does not have osteoporosis NOF Clinician’s Guide to Prevention and Treatment of Osteoporosis 2014

Which of the following is the most appropriate next step in her management? A. Continue calcium and vitamin D replacement therapy but no additional treatment for her low BMD at this time Ø This is not adequate since this patient is at high risk for future fracture. B. Start osteoporosis therapy C. Start osteoporosis therapy only if spine imaging reveals a vertebral compression fracture Ø This patient should be offered treatment regardless of whether or not she has a vertebral fracture on imaging. D. Repeat DXA scan in 3 -5 years since she does not have osteoporosis Ø A DXA scan should be repeated in 1 -2 years to assess her response to therapy. NOF Clinician’s Guide to Prevention and Treatment of Osteoporosis 2014

Questions?